New antituberculosis drugs and concepts of prophylaxis.
D000636:Aminosalicylic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use*; D001168:Arthritis / Q000139:chemically induced; D056486:Chemical and Drug Induced Liver Injury; D002648:Child; D003523:Cycloserine / Q000627:therapeutic use; D004342:Drug Hypersensitivity; D004352:Drug Resistance, Microbial; D004977:Ethambutol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005000:Ethionamide / Q000627:therapeutic use; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity; D007612:Kanamycin / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects; D008177:Lupus Vulgaris / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013307:Streptomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014374:Tuberculin Test; D014376:Tuberculosis / Q000517:prevention & control*; D014756:Viomycin / Q000627:therapeutic use
D000636:Aminosalicylic Acids; D000995:Antitubercular Agents; D011718:Pyrazinamide; D007612:Kanamycin; D004977:Ethambutol; D003523:Cycloserine; D005000:Ethionamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin; D014756:Viomycin